These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35318617)

  • 21. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.
    AlSharoqi IA; Aljumah M; Bohlega S; Boz C; Daif A; El-Koussa S; Inshasi J; Kurtuncu M; Müller T; Retief C; Sahraian MA; Shaygannejad V; Slassi I; Taha K; Zakaria M; Sørensen PS
    Neurol Ther; 2020 Jun; 9(1):55-66. PubMed ID: 32297127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy.
    Filippi M; Ferrè L; Zanetta C; Rizzi C; Pessina G; Assogna F; Rocca MA
    Front Neurol; 2024; 15():1379712. PubMed ID: 38638312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.
    Boyko AN; Boyko OV
    Degener Neurol Neuromuscul Dis; 2018; 8():35-44. PubMed ID: 30050387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
    Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
    BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
    Meuth SG; Bayas A; Kallmann B; Linker R; Rieckmann P; Wattjes MP; Mäurer M; Kleinschnitz C
    Expert Opin Pharmacother; 2022 Sep; 23(13):1503-1510. PubMed ID: 35930260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice.
    Yamout B; Alroughani R; Inshasi J; Farouk S; Abdulla F; Al-Jarki NY; Alasmi A; Al Fahad S; Alkhabouri J; Al-Saffar K; Benedetti B; Canibano B; Deleu D; Hassan A; Sarathchandran P; Shatila A; Abouelnaga M; Thakre M; Szolics M; Boshra A
    Neurol Ther; 2024 Oct; 13(5):1321-1335. PubMed ID: 39097537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP; Vermersch P
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Cortese R; Testa G; Assogna F; De Stefano N
    CNS Drugs; 2024 Apr; 38(4):267-279. PubMed ID: 38489020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
    Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W; Amin A; Ashton L; Herbert A
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.
    Gasperini C; Ruggieri S; Pozzilli C
    Ther Clin Risk Manag; 2010 Sep; 6():391-9. PubMed ID: 20856685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).
    Patti F; Visconti A; Capacchione A; Roy S; Trojano M;
    Ther Adv Neurol Disord; 2020; 13():1756286420922685. PubMed ID: 32587633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4.
    Centonze D; Amato MP; Brescia Morra V; Cocco E; De Stefano N; Gasperini C; Gallo P; Pozzilli C; Trojano M; Filippi M
    Ther Adv Neurol Disord; 2023; 16():17562864231183221. PubMed ID: 37434878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.
    Karussis D; Petrou P
    Immunol Res; 2018 Dec; 66(6):642-648. PubMed ID: 30443887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France.
    Ciron J; Bourre B; Castelnovo G; Guennoc AM; De Sèze J; Ben-Amor AF; Savarin C; Vermersch P
    Neurol Ther; 2024 Jun; 13(3):503-518. PubMed ID: 38488979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.